Proposed recommendations for 2-dose HPV vaccination

Elissa Meites, MD, MPH
Division of Viral Diseases
Advisory Committee on Immunization Practices
October 19, 2016
Background

- Three HPV vaccines are licensed for use in the United States:
  - 9-valent HPV vaccine (9vHPV, Gardasil 9, Merck)
  - Quadrivalent HPV vaccine (4vHPV, Gardasil, Merck)
  - Bivalent HPV vaccine (2vHPV, Cervarix, GlaxoSmithKline)
- Recently, 9vHPV was approved by the FDA for use in a 2-dose series for girls and boys at ages 9–14 years.
Current ACIP recommendations

- HPV vaccine is recommended for routine vaccination at age 11 or 12 years. The vaccination series can be started beginning at age 9 years.
- ACIP also recommends HPV vaccination for:
  - Females age 13 through 26 years not vaccinated previously,
  - Males age 13 through 21 years not vaccinated previously*
  - Immunocompromised persons (including those with HIV infection) and men who have sex with men through age 26 years, if not vaccinated previously

* Males aged 22 through 26 years may be vaccinated
Rationale for vote

- HPV vaccines are highly effective and safe, and a powerful prevention tool for reducing the burden of HPV infections and associated disease.
- Evidence suggests that a 2-dose schedule (0, 6–12 months) will have efficacy equivalent to a 3-dose schedule (0, 1–2, 6 months) if the HPV vaccination series is initiated before the 15th birthday.
Proposed recommendations
Outline of proposed recommendations

- Routine and catch-up age groups (no changes)
- **Dosing schedules**
- Persons with prior vaccination
- Interrupted schedules
- Special populations
- Medical conditions
- Contraindications and precautions (no changes)
- Summary
ACIP recommends routine HPV vaccination for girls and boys at age 11 or 12 years. Vaccination can be given starting at age 9 years.

ACIP also recommends vaccination for females through age 26 years and for males through age 21 years who were not adequately vaccinated previously. Males aged 22 through 26 years may be vaccinated.

(See also: Special populations, Medical conditions)
Proposed: Dosing schedules

- For persons initiating vaccination before the 15th birthday, the recommended immunization schedule is 2 doses of HPV vaccine. The second dose should be administered 6–12 months after the first dose (0, 6–12 month schedule).*

- For persons initiating vaccination on or after the 15th birthday, the recommended immunization schedule is 3 doses of HPV vaccine. The second dose should be administered 1–2 months after the first dose, and the third dose should be administered 6 months after the first dose (0, 1–2, 6 month schedule).*

* See footnote defining minimum intervals
Proposed: Persons with prior vaccination

- Persons who initiated vaccination with 9vHPV, 4vHPV, or 2vHPV before the 15th birthday, and received 2 doses at the recommended dosing schedule, or 3 doses at the recommended dosing schedule, are considered adequately vaccinated.

- Persons who initiated vaccination with 9vHPV, 4vHPV, or 2vHPV on or after the 15th birthday, and received 3 doses at the recommended dosing schedule, are considered adequately vaccinated.
Proposed: Persons with prior vaccination

- 9vHPV may be used to continue or complete a series started with 4vHPV or 2vHPV.
- For persons who have been adequately vaccinated with 2vHPV or 4vHPV, there is no ACIP recommendation for additional vaccination with 9vHPV.

Proposed: Interrupted schedules

- If the vaccine schedule is interrupted, the vaccination series does not need to be restarted.
- Number of recommended doses is based on age at administration of the first dose.
Background on minimum intervals

- Current ACIP guidelines:
  - Minimum interval between first and third dose is 24 weeks.
- In 2-dose and 3-dose 9vHPV trials:
  - 6-month interval was defined as 180 days (or 26 weeks).
  - Participants received vaccine within 4 weeks of target date.
- 9vHPV trial data support a minimum interval of 5 months (or 22 weeks).
- Updated FDA label states a minimum interval of 5 months between doses in a 2-dose series.
Proposed: Minimum intervals

- Footnote defining minimum intervals:
  - In a 2-dose series of HPV vaccine, the minimum interval is 5 months between the first and second dose.
  - In a 3-dose series of HPV vaccine, the minimum intervals are 1 month between the first and second dose, 3 months between the second and third dose, and 5 months between the first and third dose.
  - A vaccine dose administered at a shorter interval should be readministered.
Proposed: Special populations

- For children with history of sexual abuse or assault, ACIP recommends routine HPV vaccination beginning at age 9 years.
Proposed: Special populations

- For gay, bisexual, and other men who have sex with men (MSM), ACIP recommends routine HPV vaccination as for all adolescents, and initiation of vaccination through age 26 years for those who were not adequately vaccinated previously. For transgender persons, ACIP recommends HPV vaccination through age 26 years for those who were not adequately vaccinated previously.

ACIP recommends HPV vaccination for immunocompromised females and males aged 9 through 26 years with three doses of HPV vaccine (0, 1–2, 6 months). Persons who should receive 3 doses are those with primary or secondary immunocompromising conditions that might reduce cell-mediated or humoral immunity, such as B lymphocyte antibody deficiencies, T lymphocyte complete or partial defects, HIV infection, malignant neoplasm, transplantation, autoimmune disease, or immunosuppressive therapy, since immune response to vaccination may be attenuated.*

* The recommendation for a 3-dose schedule does not apply to children aged <15 years with asplenia, asthma, chronic granulomatous disease, chronic heart/liver/lung/renal disease, CNS anatomic barrier defects (e.g., cochlear implant), complement deficiency, diabetes, or sickle cell disease.
Contraindications and precautions (no changes)

- Contraindications and precautions, including those related to pregnancy, are unchanged from previous recommendations.
- Adverse events occurring after administration of any vaccine should be reported to the Vaccine Adverse Event Reporting System (VAERS). Reports can be submitted to VAERS online, by fax, or by mail. Additional information about VAERS is available by telephone (1-800-822-7967) or online ([https://vaers.hhs.gov](https://vaers.hhs.gov)).

Markowitz 2014, Petrosky 2015
ACKNOWLEDGMENTS

- ACIP HPV Vaccines Work Group
  - ACIP Members
    - Allison Kempe (Chair)
    - Cynthia Pellegrini
    - Jose Romero
  - Ex Officio Members
    - Carolyn Deal (NIH)
    - Bruce Gellin (NVPO)
    - Jeff Roberts (FDA)
    - Joohee Lee (FDA)
  - CDC Lead
    - Lauri Markowitz

- Consultants
  - Joseph Bocchini
  - Tamera Coyne-Beasley
  - John Douglas
  - Sam Katz
  - Aimee Kreimer (NCI)
  - Debbie Saslow (ACS)
  - Rodney Willoughby

- Liaison Representatives
  - Shelley Deeks (NACCI)
  - Linda Eckert (ACOG)
  - Sandra Fryhofer (ACP)
  - Amy Middleman (SAHM)
  - Chris Nyquist (AAP)
  - Sean O’Leary (PIDS)
  - Margot Savoy (AAFP)
  - Patricia Whitley-Williams (NMA)
  - Jane Zucker (AIM)

- CDC Contributors
  - Jorge Arana
  - Harrell Chesson
  - Robin Curtis
  - Julianne Gee
  - Elissa Meites
  - Jeanne Santoli
  - Mona Saraiya
  - Shannon Stokley
  - Lakshmi Sukumaran
  - Elizabeth Unger
Recommendation vote
Summary

- Proposed recommendation: ACIP recommends a 2-dose schedule of HPV vaccine for girls and boys who initiate the vaccination series at ages 9 through 14 years
- Proposed category: Category A recommendation
Discussion and vote

- Routine and catch-up age groups (no changes)
- **Dosing schedules**
- **Persons with prior vaccination**
- Interrupted schedules
- Special populations
- Medical conditions
- Contraindications and precautions (no changes)
- Summary